---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-062805"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:43:59.190042+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma terminates UMB license, enters evaluation license and option for CNS-homing peptides

## Summary
- Terminates 2021 Master License Agreement with University of Maryland, Baltimore effective June 30, 2025.
- Gains exclusive evaluation license for CNS-homing peptides for non-clinical research through March 31, 2026.
- Holds option to negotiate a commercial license for neuroinflammatory disease; exercise requires $1,000 fee and plan.
- Derived IP created during evaluation automatically assigned to UMB; if option exercised, it enters new license.
- U.S. Government retains rights under Federal IP Policy; agreement subject to existing third-party commitments.

## SEC filing metadata
- accession: 0001213900-25-062805
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390025062805/0001213900-25-062805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390025062805/ea0248611-8k_silo.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-062805
- JSON: https://secwatch.observer/filing/0001213900-25-062805.json
- Plain text: https://secwatch.observer/filing/0001213900-25-062805.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.